Skip to main content
. 2020 May 15;10:763. doi: 10.3389/fonc.2020.00763

Table 1.

Key 3rd line trials for metastatic gastric cancer.

Name of trial ICI Comp N OS (months) PFS (months) ORR (%) References
ICI Comp HR ICI Comp HR ICI Comp
ATTRACTION-2 Nivo Placebo 493 5.3 4.1 0.6 1.6 1.4 0.6 11 0 (35)
KEYNOTE-059 Pembro NA 259 5.6 NA NA 2.0 NA NA 12 NA (36)
JAVELIN 300 Avel Pacli or Irino 371 4.6 5.0 1.1 1.4 2.7 1.7 2 4 (23)

ICI, immune checkpoint inhibitor; Comp, comparator arm; N, number of patients enrolled in the study; ORR, objective response rate; nivo, nivolumab; pembro, pembrolizumab; pacli, paclitaxel; avel, avelumab; irino, irinotecan.